Dietary Polyphenols and Glycation in Renal Insufficiency
NCT ID: NCT02524938
Last Updated: 2023-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
9 participants
INTERVENTIONAL
2016-06-01
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will have two phases - phase I, an interventional study of 3 months followed by phase II, an observational study of 21 months.
In phase I, subjects will be randomized into 2 groups: CGA-enriched diet group, or control (habitual) diet group. The treatment group will be provided with a chlorogenic acid-rich food (coffee) with instructions to achieve an intake of 400 mg per day (equivalent to 3-4 coffee cups per day) for 12 weeks. The control group will receive a conventional coffee low in chlorogenic acid.
Participants will attend three sessions during phase I; baseline, 6 weeks, and 12 weeks. At baseline, general information, medical history, dietary habits and medication use will be recorded and a Food Frequency Questionnaire completed. Urine and blood samples will be collected and blood pressure, waist circumference, height and weight recorded. Participants' diet over the previous 3 days will be assessed by estimated food diary analysis.
In phase II, written dietary recommendations will be provided at three time points (months 6, 12 and 24) - treatment group to achieve a CGA-rich diet (total polyphenol intake of at least 1g per day, and at least 400mg per day of CGA) and standard dietary advice for the control group. Anthropometric/dietary data will be collected as well as blood and urine samples to assess markers of renal function, glycation and oxidative stress, and proteomic markers of cardiovascular disease, coronary artery disease and diabetes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profile of Men and Women With Insulin Resistance.
NCT01766570
The Effect of High and Low Roasted Coffee on Vascular Response
NCT01813981
Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects with Type 2 Diabetes
NCT06895018
Effects of Cranberry Consumption in Vascular Function in Healthy Individuals
NCT02517775
Absorption of Phenolic Acids From Coffee in Humans
NCT01912144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)
Chlorogenic Acid (CGA) enriched coffee
Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.
Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)
Control group
Conventional coffee (habitual diet)
Conventional coffee
Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chlorogenic Acid (CGA) enriched coffee
Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.
Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)
Conventional coffee
Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronic renal insufficiency with persistent eGFR of 35-60mL/min for at least three months
* fluent in English
Exclusion Criteria
* malignancy
* transplant recipient
* hyperthyroidism
* hypothyroidism
* high dose glucocorticoids (≥250 mg)
* body mass index (BMI) ≥ 45 kg/m2
* special dietary requirements
* take creatine, antioxidants or vitamin supplements
* smoker
* pregnant
* consume \>4 cups of tea/coffee per day
* consume \>5 portion of fruits and vegetables per day
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Glasgow
OTHER
NHS Greater Glasgow and Clyde
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emilie Combet, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Glasgow
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NHS Greater Glasgow and Clyde
Glasgow, , United Kingdom
University of Glasgow
Glasgow, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GN15DI242
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.